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Abstract
MicroRNAs (miRNAs) are potential biomarkers of most pregnancy complica-
tions. In recent years, miR-210 has been shown as one of the main biomarkers, 
detected at different stages of pregnancy and associated with various diseases, 
including pre-eclampsia (PE). However, miR-210 is not reported as a marker of 
PE in about half of the studies. We filtered available published RNA-seq data 
and miRNAs associated with PE, including or excluding miR-210, obtained from 
the PregMiR database. For further analysis we only considered miRNAs ap-
pearing in at least four different studies. We observed that miR-152, miR-1 and 
miR-193b were only detected in studies with a changed miR-210 level, whereas 
miR-27a, miR-29a, miR-130a and miR-519b were detected in studies without 
miRNA-210  differential expression. Common biomarkers of PE are miR-182, 
miR-126, miR-155, miR-181a, miR-18a, miR-195, miR-21, miR-223, miR-335, miR-
517c, miR-518b, miR-518e and let-7f. Based on the obtained data and taking into 
account the direction of differential miRNA expression, it can be assumed that 
the most likely mechanisms of PE development in the early pregnancy stage 
are either upregulation of miR-210, miR-152, miR-518b and downregulation of 
miR-126; or upregulation of miR-126 and downregulation of miR-182 and miR-
518b. Late stages of PE are determined by miR-210, miR-152, miR-518b, miR-21, 
miR-155, miR-181a, miR-182, miR-193b-3p, miR-517c, miR-518e (upregulation) 
and miR-126, miR-18a, miR-195, miR-223, let-7f (downregulation); or miR-27a, 
miR-29a, miR-130a and miR-519d, miR-517c, miR-518e miR-155, miR-126, miR-
181a, miR-195 (upregulation) and miR-223, miR-18a, miR-182 (downregulation). 
The presented results allow speculation about the influence of certain miRNAs 
on PE development in the context of the presence or absence of miR-210 differ-
ential expression, but additional experimental studies are required to evaluate 
the findings.
Keywords: microRNA, pregnancy complications, miR-210, pre-eclampsia, bio-
informatics analysis.
Introduction
Pre-eclampsia (PE) is a complication of pregnancy characterized by the onset of 
hypertension and proteinuria after 20 weeks of gestation. It is one of the leading 
causes of maternal and neonatal mortality and morbidity worldwide. Despite nu-
merous studies, the origin and pathogenesis of PE remain unclear and accurate 
prognostic biomarkers of PE are lacking to date. There is evidence that PE is not 
a single disorder but a syndrome with many etiologies (Sibai, Dekker and Kup-
ferminc, 2005). 
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Short (21–25 nucleotides) noncoding RNAs, miR-
NAs negatively regulate gene expression by binding to 
the 3′-untranslated region of their target mRNAs (Mott 
and Mohr, 2015). Important roles are played by miRNAs 
in diverse biological processes, including pregnancy. 
Many studies have identified aberrant expression of dif-
ferent miRNAs in the placentas and blood from women 
with PE. Also, certain miRNAs were shown to be poten-
tial prognostic biomarkers for PE (Choi et al., 2013). 
The most identified differentially expressed miRNA 
in PE is miR-210 — a hypoxia-responsive miRNA which 
is upregulated in many different types of cells under hy-
poxic conditions (Takizawa et al., 2012). The gene en-
coding miR-210 (MIR210) is located on the short arm 
of chromosome 11 (11p15.5) within the intron of long 
noncoding RNA AK123483. The MIR210 promoter con-
tains binding sites of Hypoxia-Inducible Factor 1-alpha 
(HIF1α), which induces expression of miR-210  pla-
centa, endothelium and trophoblast cells. Expression 
of MIR210  can be induced by Tumor Necrosis Factor 
alpha (TNFα), Nuclear Factor kappa B (NF-κB) and 
after activation of Toll-like Receptor 3 (TLR3). Targets 
of miR-210 are involved in mitochondrial metabolism, 
angiogenesis, DNA damage response, cell proliferation, 
and apoptosis (Bavelloni et al., 2017). Although miR-
NA-210  is most often mentioned in studies related to 
oncology, different pregnancy complications are associ-
ated with miRNA-210: gestational hypertension (Hro-
madnikova et al., 2017), gestational diabetes mellitus 
(Poirier, Desgagne, Guerin and Bouchard, 2017), and 
preterm birth (Östling, Kruse, Helenius and Lodefalk, 
2019). In most studies (Pineles et al., 2007; Zhu et al., 
2009; Enquobahrie et al., 2011; Gunel et al., 2011; Ishi-
bashi et al., 2012; Betoni et al., 2013; Ura et al., 2014; 
Weedon-Fekjaer et al., 2014; Jiang et al., 2015; Li et al., 
2015; Zhang et al., 2015; Munaut et al., 2016; Vashukova 
et al., 2016; Jairajpuri et al., 2017; Awamleh et al., 2019), 
miR-210  was found to be upregulated in the placenta, 
but miR-210  was also identified among differentially 
expressed miRNA in the plasma or serum of PE pa-
tients. Moreover, increased levels of miR-210 were de-
tected in plasma samples before clinical manifestations 
of PE. However, miR-210  is not reported as a marker 
of PE in about half of the studies using both blood and 
placenta samples (Guo et al., 2009; Mayor-Lynn et al., 
2011; Noack et al., 2011; Yang et al., 2011; Wang et al., 
2012; Wu et al., 2012; Choi et al., 2013; Li et al., 2013; 
Akehurst et al., 2015; Yang et al., 2015; Sandrim et al., 
2016; Gunel et al., 2017; Pei-Yin et al., 2017; Xu et al., 
2017; Lykoudi et al., 2018; Martinez-Fierro et al., 2018; 
Timofeeva et al., 2018; Yoffe et al., 2018), so there is no 
clear understanding of regulatory pathways associated 
with miRNA-210 in PE.
The aim of our study is to compare and determine 
the influence of certain miRNAs on PE development in 
the context of the presence or absence of miR-210 differ-
ential expression. These findings may contribute to our 
understanding of molecular mechanisms involved in PE 
and identifying specific diagnostic markers for PE.
Materials and methods
Data analysis of miRNAs linked with preeclampsia. 
We obtained miRNAs linked with preeclampsia from 
the manually curated pregnancy pathology database 
PregMiR (https://pregmir.ott.ru/). We included miRNA 
genes in the analysis only if their differential expression 
between samples with preeclampsia and normal sam-
ples was significant (adjusted p-value < 0.05). In order 
to compare gene regulation by miRNA in studies that 
list miR-210  among differentially expressed miRNA 
genes and studies that do not contain information about 
miR-210, we filtered the PregMiR database and further 
grouped miRNAs according to gestational age. We also 
performed a search for the identification of preeclamp-
sia miRNA expression profiling studies. We undertook a 
web-based search in Gene Expression Omnibus (GEO, 
www.ncbi.nlm.nih.gov/geo/) using search term (“pre-
eclampsia” [MeSH Terms] OR preeclampsia [All Fields]) 
AND “Homo sapiens” [porgn] AND (“Non-coding 
RNA profiling by array”[Filter] OR “Non-coding RNA 
profiling by high throughput sequencing” [Filter]). All 
the relevant studies were further reviewed manually to 
include studies of miRNA and no other types of non-
coding RNAs. For further analysis we only considered 
miRNAs appearing in at least four different studies that 
used both blood and placenta samples.
Target genes prediction. Predicted targets for miR-
NAs were obtained from miRDB database v.6.0. Genes 
with target prediction score equal to 80 and above were 
included in further analysis.
GO enrichment analysis. R packages ClusterPro-
filer v.3.14.0 (Yu, Wang, Han and He, 2012) and DOSE 
3.12.0  (Yu, Wang, Han and He, 2014)  were applied to 
perform GO enrichment analysis (biological process 
terms), KEGG enrichment and DisGeNET enrichment 
analysis. In order to adjust p-values, false discovery rate 
(FDR) was calculated using the Benjamini and Hoch-
berg method. FDR <0.05 was selected as the cutoff value 
for functional and pathway enrichment analysis of dif-
ferentially expressed genes. 
Results and discussion
Base data analysis
We conducted analysis of different studies with and 
without differential expression of miR-210 in PE. After 
filtering the data in the PregMiR database, we obtained 
16 and 20 studies with and without differential expres-











sion of miRNA-210 in PE, respectively, at different stag-
es of pregnancy. 
The search for publicly available datasets for com-
parison of miRNA between preeclampsia and normo-
tension resulted in four studies conducted with mi-
croarrays and three studies  — with high-performance 
sequencing. Among the search results, only data from 
GSE114349 (RNA sequencing of miRNA from Azamleh 
et al., 2019) was included in Supplement 1, as other da-
tasets did not have significantly differentially expressed 
genes (GSE103542, GSE96983), were already listed in 
PregMiR (GSE15789, GSE119799) or did not have an 
accompanying publication (GSE84260, GSE96983).
Most studies were performed with placental miR-
NAs; circulating miRNAs appeared in only 18  studies, 
with only 5 of them in the early stages of pregnancy. Pla-
cental miRNAs are not reliable biomarkers for pregnan-
cy complications, as Menon et al. showed that miRNA 
expression changes during pregnancy (2018).
Combining data from PregMir and analysis of GEO 
data, we obtained 239 differentially expressed miRNAs 
in studies with miRNA-210 (Suppl.  1) and 126  — in 
studies without miR-210  differential expression re-
ported (Suppl.  2), amounting to 320  unique miRNAs. 
Four different miRNA genes appeared in at least four 
different studies mentioning miR-210 and four miRNA 
genes — in studies without miR-210 in listed differen-
tial expression results, and 15 miRNAs appeared in both 
cases (Figure  1). Among them three miRNAs (miR-1, 
miR-193b, miR-195) were only differentially expressed 
in placenta samples and not in serum or plasma sam-
ples. Targets of these miRNAs were enriched in 32 and 
79  KEGG pathways (89  for overlapping miRNAs ap-
pearing both in studies with and without miR-210 dif-
ferential expression), 118 and 179 disease profiles from 
DisGeNET (147 for overlapping), 458 and 771 Gene On-
tology biological process (815 for overlapping miRNAs) 
profiles for studies with and without miR-210, respec-
tively. Dotplots for 15 most enriched gene lists are pro-
vided in Figure 2a–c.
Interestingly, only targets of miRNAs that are co-
occurring with miR-210 in studies of pre-eclampsia are 
enriched in anoxia-associated genes (adjusted p-value 
0.005), which is consistent with the hypoxia-related role 
of miR-210. Both RNA groups that appear with and 
without miR-210  context are associated with systemic 
arterial pressure (adjusted p-value 2.92*10–9), as would 
be expected from PE markers. 
C19MC cluster
Of these miRNAs, one miRNA (519d) in studies without 
miR-210   Yang et al., 2011; Li et al., 2013; Yang et al., 
2015) and three (517c, 518b, 518e) in all studies (Zhu et 
al., 2009; Guo et al., 2011; Mayor-Lynn et al., 2011; Yang 
et al., 2011; Ishibashi et al., 2012; Li et al., 2013; Ura et 
al., 2014; Xu et al., 2014; Yang et al., 2015; Vashukova et 
al., 2016) were mapped to the C19MC cluster, the largest 
human miRNA gene cluster, whose expression is almost 
exclusively confined to the placenta. The cluster spans 
~100 kb on chromosome 19q13.41 and contains 54 pre-
dicted miRNA genes, 43 of which have been cloned and 
sequenced (Poirier et al., 2017). The C19MC cluster is 
regulated by genomic imprinting with only the paternal-
ly inherited allele being expressed in placenta, while the 
maternal one displays a methylation imprint (Poirier et 
al., 2017). The precise biological function of the C19MC 
cluster is unknown. It was shown that miRNAs of the 
C19MC have characteristics of oncogenes and may play 
a role in trophoblast cell proliferation, invasion, migra-
tion, intercellular communication and viral resistance 
(Poirier et al., 2017). It was reported that altered expres-
sion of 517c in the decidua is associated with recurrent 
pregnancy loss (Dong et al., 2014), and altered expres-
sion of miR-518b in the placenta—with low fetal birth 
weight (Ostling et al., 2019).
It is of note that the functioning of this cluster dif-
fers between two compared groups of miRNA studies 
Fig. 1. Venn diagram of miRNAs appearing in at least four different 
studies of miRNA in preeclampsia.
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in the direction of miR-518b expression change. In the 
context of miR-210 differential expression, miR-518b is 
upregulated in PE (Zhu et al., 2009; Ura et al., 2014; Xu 
et al., 2014) while it has decreased expression in studies 
where miR-210 levels are unchanged (Guo et al., 2011; 
Mayor-Lynn et al., 2011). This fact is important for un-
derstanding possible mechanisms of PE development, 
especially in early pregnancy terms when miR-518b is 
already detected in the plasma, as it can be used for rou-
tine screening of pregnant women according to changed 
miRNA expression profiles. It can be speculated that the 
risk group for PE is comprised of patients with upregula-
tion of both miR-210 and miR-518b or downregulation 
of miR-518b on the background of unchanged miR-
210 expression level.
miRNAs in studies with miR-210
Among analyzed miRNAs, miR-152, miR-1, and miR-
193b are detected only in studies with miRNA-210. Up-
regulation of miR-152 is found in PE placentas (Zhu et 
al., 2009; Jiang et al., 2015) and blood serum from PE 
patients (Ura et al., 2014; Li et al., 2015). One of the tar-
gets of miR-152  is the HLA-G gene (Zhu et al., 2010). 
HLA-G protects trophoblast cells from lysis by Natural 
Killer (NK) cells and contributes to the tolerance of the 
mother’s immune system to the fetus (Zhu et al., 2010). 
A reduced level of HLA-G mRNA was detected in PE 
placentas (Zhu et al., 2010). Overexpression of miR-
152  in trophoblast cells is associated with a reduction 
of HLA-G levels and increasing trophoblast lysis by NK 
cells (Zhu et al., 2010) that results in defective remod-
eling of uterine spiral arteries by the trophoblast. Also, 
miR-152 has been found to target placental growth fac-
tor (PLGF), which is synthesized in trophoblast cells and 
plays an important role in placental vessels development 
(Cai et al., 2016). In pregnancies complicated by PE, the 
level of PLGF is reduced (Cai et al., 2016). 
Results about the expression of miR-1 are conflict-
ed and inconsistent. In one study the level of miR-1  is 
increased (Zhang et al., 2015), while in others it is re-
duced in PE placentas (Zhu et al., 2009; Enquobahrie 
et al., 2011; Vashukova et al., 2016). It is possible that 
miR-1 affects the risk of PE development through its ef-
fect on calcium signaling (Enquobahrie et al., 2011) and 
through its influence on the expression of metallopep-
tidase inhibitor 3, which is involved in the regulation 
of trophoblast invasion (Lim et al., 2005; Xiang et al., 
2013). Given the heterogeneous results and the lack of 
expression of this microRNA in early pregnancy stages 
Fig. 2. a) Dotplot that depicts top 15 enriched DisGeNET pathways in miRNA targets of miRNA that do and do not co-occur with miR-210 in 
studies of preeclampsia. Dot sizes reflect sizes of gene sets, color corresponds to Bonferroni-Hochberg adjusted p-values. GeneRatio shows 
the proportion of miRNA target genes that are present in reference gene sets used to enrichment analysis. b–c) Same as a but for GO biological 
process and KEGG pathways, respectively.
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and in blood samples, it is difficult to consider it as an 
important biomarker of PE.
In all reported studies miR-193b-3p is upregulated 
in PE placentas (Ishibashi et al., 2014; Xu et al., 2014; 
Vashukova et al., 2016; Awamleh et al., 2019). There 
were no studies where miR-193b differential expression 
was detected in blood samples. Overexpression of miR-
193b-3p represses proliferation, invasion, migration and 
growth of cancer cells (Zhou et al., 2016). In experiments 
in vitro, upregulation of miR-193b-3p has been found to 
inhibit the migration and invasion of trophoblast cells 
by targeting TGF-β2 (transforming growth factor-β), 
which demonstrated significantly lower levels of mRNA 
and protein in PE placentas (Zhou et al., 2016).
miRNAs in studies without miR-210
The miRNAs miR-27a, miR-29a, miR-130a and miR-
519d were detected in more than four studies without 
miRNA-210 differential expression and are upregulated 
in all the studies reported here. 
Upregulation of miR-27a was found in plasma and 
placental tissue in studies associated with PE (Hu et al., 
2009; Li et al., 2013; Yang et al., 2015). Its gene is located 
on the chromosome 19p13.13. miR-27a is a member of 
the miR-23 ~ 27 ~ 24 cluster, participating in the pro-
cess of angiogenesis by targeting angiogenesis inhibitor 
SEMA6A, which controls the repulsion of neighbor-
ing endothelial cells. miR-27a plays an anti-adipogenic 
role disrupting the function of mitochondria, and it is 
associated with angiogenesis in cardiovascular diseases 
and endothelial apoptosis in cardiac ischemia. Its role in 
inflammation is demonstrated by increased expression 
of pro-inflammatory cytokines, such as IL-10, when ac-
tivated in TlR2  or TlR4-activated macrophages. It was 
also shown that the knockdown of miR-27a reduces 
the regulation of pro-inflammatory cytokines IL-6 and 
TNF-α, which are associated with PE (Maharaj et al., 
2016). 
The miR-29 family is associated with adult cardio-
vascular diseases, is expressed in human endothelium, 
and is involved in the process of angiogenesis. miR-29a 
is associated with pathways that are dysregulated in PE: 
the TGF-β signaling pathway, estrogen signaling path-
way, focal adhesion, and PI3K-Akt signaling pathway. 
Changes in these signaling pathways can lead to dys-
regulation of the endothelial function of the fetus, which 
is noted in PE (Zhou et al., 2017). In all studies reported 
here miR-29a was upregulated (Yang et al., 2011; Li et 
al., 2013; Yang et al., 2015), thus disrupting angiogenesis, 
causing dysregulation in the placentation.
A pro-angiogenic miRNA, miR-130a regulates ho-
meobox proteins homeobox A5 (HOXA5) and growth 
arrest homeobox (GAX) (Chen and Gorski, 2007), 
which are involved in the development of the vascula-
ture of the placenta. Research has shown that miR-130a 
attenuates endothelial cell damage by suppressing PTEN 
and activating the PI3K-Akt-NOS3  signaling pathway 
(Song et al., 2016). Increased regulation of miRNA-130a 
was found in all studies (Guo et al., 2011; Li et al., 2013; 
Yang et al., 2015), which suggests that it plays an impor-
tant role in the pathogenesis of PE.
All of those miRNAs (miR-27a, miR-29a, miR-130a 
and miR-519d) were detected in plasma and placenta in 
later stages of pregnancy, which is probably due to their 
defined roles in the development of late PE forms.
Overlapping miRNAs
In most studies miR-223 is significantly downregulated 
in PE placentas (Zhu et al., 2009; Betoni et al., 2013; Choi 
et al., 2013; Weedon-Fekjaer et al., 2014; Xu et al., 2014; 
Vashukova et al., 2016;) and blood (Yang et al., 2011; 
Li et al., 2013). Only in two studies without miR-210, 
miR-223  was upregulated in the placenta (Guo et al., 
2011; Mayor-Lynn et al., 2011). The expression of miR-
223 is regulated by several transcriptional factors, such 
as CCAAT-enhancer-binding proteins (C/EBP)-α and 
-ß and nuclear factor I-A (NFI-A) (Kapinas and Delany, 
2011). Originally, miR-223 was characterized as a hema-
topoietic regulator that affects the development of he-
matopoietic stem cells, myeloid, erythroid and lymphoid 
cells (Johnnidis et al., 2008). Further studies have shown 
that miRNA-223 is involved in osteoclastogenesis (NF-
IA), granulopoiesis (IKKα, NF-IA, E2F), erythropoiesis 
(LMO2), cell invasiveness (MEF2C), tumor suppression 
(EPB4IL3), tumorigenesis (STMN1, FBW7, KRAS, EGF, 
EGFR2, MMP9, SEPTIN6), inflammation (NLRP3, 
Pknox1), glucose uptake (GLUT-4), VSMC proliferation 
(IGF-1R), and VSMC contractile phenotype (Rho B, 
MEF2C), which are associated with oncology, type 2 di-
abetes, cardiovascular diseases and diseases of the mus-
culoskeletal system (Taïbi et al., 2014). There have also 
been studies where miR-223  is differentially expressed 
in various pregnancy complications, with the exception 
of PE, such as preterm birth (Mayor-Lynn et al., 2011; 
Tang et al., 2015; Enquobahrie et al., 2016; Gray et al., 
2017; Winger et al., 2017; Menon et al., 2019).
Involvement and the mechanism of action of let-7f 
in PE are still unclear. However, the role of let-7 family 
members in proliferation, apoptosis and inflammation 
suggests their contribution to the onset of PE via dereg-
ulation of these processes (Vashukova et al., 2016). In 
studies without miR-210, miR-let-7f was mostly down-
regulated (three cases out of five) (Yang et al., 2011; Li et 
al., 2013; Gunel et al., 2017) and was downregulated in 
the studies with miR-210 (Vashukova et al., 2016).
The miRNAs miR-335  and miR-21  are hypoxia-
upregulated (Doridot et al., 2013). Jiang et al. (2015) 
has shown that miR-335 suppresses the migration and 











invasion of trophoblast cells by regulation of endothe-
lial nitric oxide synthase (NOS3), which catalyzes the 
formation of nitric oxide (NO) from L-arginine in en-
dothelial cells. NO is involved in trophoblast invasion, 
development and function of the placenta (Jiang et al., 
2015). NOS3 has been identified as one of the suscep-
tibility genes for PE. G894T (rs1799983)  and T-786C 
(rs2070744) polymorphism in NOS3 predisposes to PE 
by decreasing the enzyme level and reducing the pro-
duction of NO (Zeng et al., 2016). PE is associated with 
a decrease in the activity of NOS3, which leads to in-
creased blood pressure (Zeng et al., 2016). However, 
the results of studies are conflicted, since in all studies, 
miRNA-335 increased and decreased in two cases (Hu et 
al., 2009; Ura et al., 2014; Jiang et al., 2015; Zhang et al., 
2015). Therefore, the effect of miR-335 remains unclear.
miR-21  enhances trophoblast proliferation and 
invasion by modulating the nodal signaling pathway. 
Targets of miR-21 are VEGF and HIF-1α, which are in-
volved in the regulation of angiogenesis. Research has 
shown that miR-21  also targets zinc finger transcrip-
tion factor SP1, which is important in placental func-
tions. SP1  controls the expression of cystathionine-γ-
lyase (CSE), responsible for the synthesis of hydrogen 
sulfide (H2S), which has a vasodilator effect important 
for correct placentation (Doridot et al., 2013). During 
gestational diabetes mellitus (Wander et al., 2017) and 
pregnancy-induced hypertension complicated with 
heart failure (Kan et al., 2019), miR-21  is differentially 
expressed. Sanders et al. (2015) showed that miR-21, iso-
lated from cervical cells, was significantly overexpressed 
in women who had a shorter gestation. The expression 
of miRNA-21  was increased in all studies with miR-
NA-210  (Jiang et al., 2015; Jairajpuri et al., 2017), and 
studies have produced contradictory results (one upreg-
ulated (Li et al., 2013) and two downregulated (Choi et 
al., 2013; Gunel et al., 2017)). 
An important role in angiogenesis is played by miR-
126 and miR-155 by enhancing the function of vascular 
endothelial growth factor VEGF. Targets of miR-126 are 
phosphoinositide-3-kinase regulatory subunit 2  (PI-
K3R2)  and sprouty-related EVH1  domain, containing 
protein 1  (SPRED1), which downregulate VEGF via 
MAP kinase and PI3 pathways (Hong, Li and Xu, 2014). 
miR-155 binds to the 3’ UTR region of CYR61 (cysteine-
rich protein 61), inducing VEGF (Zhung et al., 2014). 
It was shown that VEGF is also involved in the regula-
tion of trophoblast invasion, proliferation and differen-
tiation. (Shore et al., 1997). Interestingly, in studies with 
miR-210, miR-126 was downregulated in three cases out 
of four (Zhu et al., 2009; Ishibashi et al., 2012; Ura et al., 
2014), and in studies without miR-210, it was upregu-
lated in four cases out of five (Hu et al., 2009; Guo et al., 
2011; Yang et al., 2015; Lykoudi et al., 2018). It can be 
assumed that in these cases, the pathogenesis of PE oc-
curs via different pathways. In all studies, miR-155 was 
upregulated ( Pineles et al., 2007; Lykoudi et al., 2015; Xu 
et al., 2015; Jairajpuri et al., 2017).
A member of the miRNA 17-92  cluster, miR-18a 
is involved in the regulation of trophoblast cell activ-
ity. The target for miRNA-18a is Smad2, associated with 
TGF-β signaling, which modulates trophoblast cell in-
vasion (Xu et al., 2014). Also, miRNA-18a regulates the 
expression of estrogen receptor α-3’ (ESRα‑3’), which 
is involved in trophoblast apoptosis (Zhu et al., 2015). 
As in the case of miR-126, miR-18a has different regula-
tion between studies with (downregulation) and without 
(upregulation) miR-210 (Zhu et al., 2009; Li et al., 2013; 
Xu et al., 2014; Yang et al., 2015; Vashukova et al., 2016; 
Jairajpuri et al., 2017).
Also, miR-182 affects trophoblast invasion via bind-
ing to RND3 3’ UTR region (Fang et al., 2018). It is pos-
sible that miR-182 plays a role as an immune response 
enhancer by stimulation of T helper cells via upregula-
tion of IL-2  (Serebelli, Satoh and Chan, 2012). In one 
of eight studies (the list without miR-210), miR-182 was 
downregulated in plasma in early terms (Yoffe et al., 
2018); in the rest of the studies (Pineles et al., 2007; No-
ack et al., 2011; Jiang et al., 2015; Li et al., 2015; Zhang 
et al., 2015) it was increased, which allows us to make 
an assumption about the importance of miR-182 in PE.
SPP1 and ITGB3, which are targets for miR-181a, 
are components of the focal adhesion signal pathway. 
Focal adhesions are dynamic macromolecular complex-
es comprised of integrins which bind the extracellular 
matrix (ECM) to the actin cytoskeleton and have been 
demonstrated to play an important role in embryo im-
plantation and placentation. Many of the components 
of the focal adhesion signal pathway link integrin-me-
diated signals with other signaling pathways, such as 
mTOR, PI3K, and MAPK signaling pathways (Su et al., 
2014). Additionally, miR-181a is involved in the inva-
sion and migration of trophoblasts via deregulation of 
insulin-like growth factor 2  mRNA-binding protein 
2 (IGF2BP2) (Wu et al., 2018). In all studies, miR-181a 
was upregulated (Hu et al., 2009; Zhu et al., 2009; Wu et 
al., 2012; Jiang et al., 2015; Zhang et al., 2015; Awamleh 
et al., 2019). Given its relationship with pathways in-
volved in PE, miR-181a can be considered a potential 
biomarker of PE. 
Involvement of miR-195  occurs in inhibition of 
cell invasion and migration (FASN, CCNE1), inhibition 
of cell proliferation (HSPA4L, CCNE1, AKT3), angio-
genesis and inhibition of trophoblast invasion (VEGF), 
vascular homeostasis (SMURF1), trophoblast apoptosis 
and cell cycle control (WEE1), which lead to impaired 
placentation and, therefore, to PE (Gunel et al., 2018). 
The difference in the expression of miR-195  in stud-
ies associated and unassociated with miR-210 suggests 
different mechanisms of PE in two groups of studies. 
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Differential expression of miR-195  was found only in 
placenta samples where it was downregulated in stud-
ies with miR-210 (Zhu e al., 2009; Xu et al., 2014; Vashu-
kova et al., 2016), and upregulated in studies without 
miR-210 (Hu et al., 2009).
Conclusion
The search for new biomarkers of severe pregnancy com-
plications remains a relevant task. Different miRNAs are 
among promising candidates for biomarkers of pregnan-
cy complications. One of the most popular biomarkers, 
miR-210, is a hypoxia-responsive miRNA which is asso-
ciated with various pregnancy complications including 
PE, gestational diabetes, preterm birth and others (Hro-
madnikova et al., 2017; Poirier, Desgagne, Guerin and 
Bouchard, 2017; Östling, Kruse, Helenius and Lodefalk, 
2019). However, miR-210 is not reported as a marker of 
PE in about half of the studies, which may indicate the 
presence of different pathogenetic mechanisms of PE 
development. 
Here we have shown that targets of miRNAs co-
occurring with miR-210  in studies of PE are enriched 
in anoxia-associated genes, which is consistent with the 
hypoxia-related role of miR-210. All reviewed studies re-
port miR-152 co-expression with miR-210. Research has 
found miR-152 to target placental growth factor (PLGF), 
the main biomarker of PE, which is synthesized in tro-
phoblast cells and plays an important role in placental 
angiogenesis (Cai et al., 2016). Apparently, these mecha-
nisms of pathogenesis of PE have a common basis. This 
suggests that both miR-210-associated biomarkers and 
PLGF can serve as predictors of early PE. On the other 
hand, at least half of the cases of PE require additional 
biomarkers. Therefore, our study aims to determine the 
effect of certain miRNAs on PE development in the con-
text of the presence or absence of miR-210 differential 
expression. 
Based on data from studies of miRNA expression, 
we can assume several different mechanisms of PE devel-
opment. The first is related to early detection of upregu-
lated miR-210  and co-expressed miR-152, miR-518b 
and downregulation of miR-126 in plasma of pregnant 
women followed by upregulation of miR-21, miR-155, 
miR-181a, miR-182, miR-193b-3p, miR-517c and miR-
518e and downregulation of miR-18a, miR-195, miR-
223  and let-7f in placentas in later stages. The second 
mechanism of PE development may be associated with 
detection of such biomarkers as miR-126  (upregulat-
ed) and miR-182, miR-518b (downregulated) in blood 
plasma in early pregnancy. And the third mechanism is 
apparently determined by changes of specific miRNAs 
not associated with miR-210 in late stages of pregnancy: 
miR-27a, miR-29a, miR-130a and miR-519d (upregu-
lated); and common biomarkers: miR-517c, miR-518e, 
miR-155, miR-126, miR-181a, miR-195 (upregulated) 
and miR-223, miR-18a, miR-182 (downregulated).
Currently there are few studies of miRNA-seq on 
early stages of pregnancy. We understand that this study 
is theoretical in nature. All of this is a certain limitation 
of the work and our findings need to be tested in experi-
mental studies. However, despite this we believe that our 
results elucidate the mechanisms of PE pathogenesis and 
can be useful in screening programs in the future.
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